Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$2.05
+4.1%
$1.76
$0.76
$2.73
$77.47M1.3185,124 shs67,707 shs
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$1.03
-1.9%
$1.01
$0.71
$1.61
$64.49M1.19145,938 shs40,411 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$0.71
+1.3%
$0.70
$0.50
$1.55
$31.53M1.55285,828 shs65,780 shs
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$55.93
-1.3%
$55.46
$51.26
$77.33
$181.77M0.2819,588 shs18,722 shs
Westaim Corp. stock logo
WEDXF
Westaim
$22.02
-1.4%
$22.99
$16.62
$25.98
$738.88M0.26,645 shs4,004 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-6.19%-23.64%+12.57%+93.14%+42.75%
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-0.94%+1.94%-3.67%+3.96%-2.78%
DarioHealth Corp. stock logo
DRIO
DarioHealth
-2.64%-0.04%+5.11%-0.54%-51.05%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
+0.46%-0.87%+2.77%+6.90%-17.40%
Westaim Corp. stock logo
WEDXF
Westaim
-0.98%+1.22%-5.84%+3.43%+657.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Corporation stock logo
APYX
Apyx Medical
1.8291 of 5 stars
0.04.00.04.21.61.70.6
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
1.559 of 5 stars
3.51.00.00.02.20.00.6
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.9365 of 5 stars
3.30.00.00.02.90.81.3
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
2.2432 of 5 stars
0.01.01.74.12.91.71.3
Westaim Corp. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Corporation stock logo
APYX
Apyx Medical
2.67
Moderate BuyN/AN/A
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
3.00
Buy$5.50433.98% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
2.67
Moderate Buy$2.00182.09% Upside
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
0.00
N/AN/AN/A
Westaim Corp. stock logo
WEDXF
Westaim
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UTMD, WEDXF, DRIO, CTSO, and APYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/19/2025
DarioHealth Corp. stock logo
DRIO
DarioHealth
Litchfield Hills Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
5/2/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$48.10M1.61N/AN/A$0.38 per share5.39
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$35.33M1.83N/AN/A$0.20 per share5.15
DarioHealth Corp. stock logo
DRIO
DarioHealth
$28.03M1.12N/AN/A$2.11 per share0.34
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$40.90M4.44$4.88 per share11.45$34.62 per share1.62
Westaim Corp. stock logo
WEDXF
Westaim
$17.04M43.36N/AN/A$23.28 per share0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$13.87M$3.7814.80N/A33.00%10.74%10.27%7/24/2025 (Estimated)
Westaim Corp. stock logo
WEDXF
Westaim
-$16.18M-$2.17N/AN/A-253.76%-9.36%-8.82%8/12/2025 (Estimated)

Latest UTMD, WEDXF, DRIO, CTSO, and APYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.07N/AN/AN/A$9.79 millionN/A
5/14/2025Q1 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million
5/14/2025Q1 2025
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million
5/14/2025Q1 2025
Westaim Corp. stock logo
WEDXF
Westaim
-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) million
5/8/2025Q1 2025
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million
4/29/2025Q1 2025
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A$0.92N/A$0.92N/A$9.71 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Corporation stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$1.222.18%N/A32.28%3 Years
Westaim Corp. stock logo
WEDXF
Westaim
$0.090.41%N/AN/A N/A

Latest UTMD, WEDXF, DRIO, CTSO, and APYX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/16/2025
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
quarterly$0.30502.3%6/16/20256/16/20257/3/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Corporation stock logo
APYX
Apyx Medical
3.21
5.45
4.64
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.98
2.61
2.30
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.26
2.01
1.77
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A
22.29
20.29
Westaim Corp. stock logo
WEDXF
Westaim
N/A
11.40
11.40

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
55.33%
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
69.60%
Westaim Corp. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
15.20%
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.30%
DarioHealth Corp. stock logo
DRIO
DarioHealth
11.20%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
7.40%
Westaim Corp. stock logo
WEDXF
Westaim
4.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Corporation stock logo
APYX
Apyx Medical
27037.79 million32.05 millionOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.61 million58.48 millionOptionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
20044.46 million39.48 millionOptionable
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
1803.25 million3.01 millionNot Optionable
Westaim Corp. stock logo
WEDXF
Westaim
733.56 million32.14 millionNot Optionable

Recent News About These Companies

The Westaim Corporation Reports Q1 2025 Results
Westaim completes acquisition of ManhattanLife
The Westaim Corp WEDXD
Westaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)
The Westaim Corporation appoints CRO
Westaim Corporation: A Bargain In The Asset Management World
Westaim Corporation: Still Undervalued Based On NAV
The Westaim Corporation (WEDXF)
Westaim: Q1 Earnings Snapshot
The Westaim Corporation Reports Q1 2024 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apyx Medical stock logo

Apyx Medical NASDAQ:APYX

$2.05 +0.08 (+4.06%)
Closing price 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.24%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$1.03 -0.02 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$1.03 0.00 (0.00%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

DarioHealth stock logo

DarioHealth NASDAQ:DRIO

$0.71 +0.01 (+1.29%)
Closing price 03:59 PM Eastern
Extended Trading
$0.70 0.00 (-0.56%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Utah Medical Products stock logo

Utah Medical Products NASDAQ:UTMD

$55.93 -0.76 (-1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$55.80 -0.13 (-0.24%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Westaim stock logo

Westaim OTCMKTS:WEDXF

$22.02 -0.32 (-1.43%)
As of 03:53 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.